Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement
News Aug 15, 2005
Antibodies by Design and JPT Peptide Technologies have announced the start of a co-marketing agreement between the two companies.
Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT.
Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan.
"We are very glad to have reached an agreement with JPT which bears enormous advantages for both companies, and also for our customers," stated Dieter Lingelbach, Head of the Antibodies by Design division and Senior Vice President of MorphoSys AG.
He adds, "Both companies are absolute specialists in their field and belong to the top addresses for antibody development and innovative peptide-based services in Europe."
"MorphoSys' unique antibody repertoire is the ideal complement to our immunology tools program which includes the peptide array platforms PepSpot™ and PepStar™ plus the novel PepMix™ technology for effective T-lymphocyte stimulation," said Holger Wenschuh, Managing Director of JPT.
He adds, "This co-marketing agreement will allow both companies to address new customers and offer them an even wider package of immunology services."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE